X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Cadila Healthcare with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs TEVA PHARMA (Israel) - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 CADILA HEALTHCARE   TEVA PHARMA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-17
TEVA PHARMA
Dec-13
CADILA HEALTHCARE/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs4602,704-   
Low Rs3052,349-   
Sales per share (Unadj.) Rs92.11,551.8-  
Earnings per share (Unadj.) Rs14.896.9-  
Cash flow per share (Unadj.) Rs18.5222.4-  
Dividends per share (Unadj.) Rs3.2084.86-  
Dividend yield (eoy) %0.83.4 24.9%  
Book value per share (Unadj.) Rs68.01,723.8-  
Shares outstanding (eoy) m1,023.74848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.21.6 255.1%   
Avg P/E ratio x25.826.1 99.1%  
P/CF ratio (eoy) x20.711.4 182.2%  
Price / Book Value ratio x5.61.5 383.9%  
Dividend payout %21.687.5 24.7%   
Avg Mkt Cap Rs m391,5812,142,404 18.3%   
No. of employees `00016.944.9 37.5%   
Total wages/salary Rs m15,0020-   
Avg. sales/employee Rs Th5,594.529,278.9 19.1%   
Avg. wages/employee Rs Th890.10-   
Avg. net profit/employee Rs Th899.91,829.0 49.2%   
INCOME DATA
Net Sales Rs m94,2951,315,941 7.2%  
Other income Rs m1,2860-   
Total revenues Rs m95,5811,315,941 7.3%   
Gross profit Rs m19,036360,371 5.3%  
Depreciation Rs m3,750106,369 3.5%   
Interest Rs m45025,847 1.7%   
Profit before tax Rs m16,122228,155 7.1%   
Minority Interest Rs m3381,036 32.6%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3-149,771 0.0%   
Tax Rs m1,289-2,786 -46.3%   
Profit after tax Rs m15,16882,206 18.5%  
Gross profit margin %20.227.4 73.7%  
Effective tax rate %8.0-1.2 -654.9%   
Net profit margin %16.16.2 257.5%  
BALANCE SHEET DATA
Current assets Rs m60,223888,782 6.8%   
Current liabilities Rs m53,058775,093 6.8%   
Net working cap to sales %7.68.6 88.0%  
Current ratio x1.11.1 99.0%  
Inventory Days Days7091 76.9%  
Debtors Days Days8896 91.9%  
Net fixed assets Rs m72,984429,815 17.0%   
Share capital Rs m1,0243,239 31.6%   
"Free" reserves Rs m68,5760-   
Net worth Rs m69,6001,461,761 4.8%   
Long term debt Rs m24,684672,870 3.7%   
Total assets Rs m152,2073,007,347 5.1%  
Interest coverage x36.89.8 374.7%   
Debt to equity ratio x0.40.5 77.0%  
Sales to assets ratio x0.60.4 141.6%   
Return on assets %10.33.6 285.6%  
Return on equity %21.85.6 387.5%  
Return on capital %17.94.9 363.6%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m10,4060-   
CASH FLOW
From Operations Rs m13,495209,693 6.4%  
From Investments Rs m-29,103-74,303 39.2%  
From Financial Activity Rs m23,158-251,541 -9.2%  
Net Cashflow Rs m7,556-116,151 -6.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 64.78 Rs / USD

Compare CADILA HEALTHCARE With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  

Compare CADILA HEALTHCARE With: DIVIS LABORATORIES  ALKEM LABORATORIES  TTK HEALTHCARE  BIOCON LTD  GSK PHARMA  



Today's Market

Of Mr Modi Providing Impetus to Defense Industry and Key Stocks in Action Today(Pre-Open)

Addressing the Uttar Pradesh Investors Summit, Mr. Modi announced the creation of a defense industrial corridor in Bundelkhand.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Feb 21, 2018 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE - GLENMARK PHARMA COMPARISON

COMPARE CADILA HEALTHCARE WITH

MARKET STATS